STC’s publication approved for B cell response in Tuberculosis

Last week STC Biologics, Inc. announced the approval of its publication on B cell response in adults with latent Tuberculosis in the Global Vaccine and Immunology Journal. These efforts were lead by Dr. Lisa Ganley-Leal, Director of Infectious Diseases, with the help of  Dr. Thomas Schneider, Director of Biology, from STC Biologics Inc and also accredited to the on going successful collaborations between Boston University and STC Biologics, Inc. On the link below, the full published PDF file can be found:

B cell paper TB July 2016